Hypertension is an important risk factor concomitant with cardiovascular disease (CVD) states, which is why we set out to evaluate Californian red worm hydrolysates on antihypertensive activity both , , using rabbit aortic rings and using hypertensive induced rats. The worms were manually separated, washed with water, purged for 4 h with 4 % sodium bicarbonate, sacrificed with 7 % saline, and finally washed with drinking water. The antihypertensive capacity was performed by measuring angiotensin-converting enzyme inhibition; for the assays, rabbit aorta was used to measure relaxation; for the assays, rats with induced hypertension were used to perform acute (hypotension) and chronic assays, using captopril as a control in all assays. With respect to angiotensin-converting enzyme (ACE) inhibition, the EC50 value of the worm hydrolysate was found to be 358 ppm; with respect to the analysis in aortic rings, it was found that the mechanisms of action of the hydrolysate are endothelium-dependent, presenting a maximum relaxation of 35 %. With respect to the assays, the hypotensive test showed that the hydrolysate can reduce blood pressure by up to 32 % in only 2 h, while the chronic analysis showed that the hydrolysate at 150 ppm did not present statistically significant differences with the control (captopril) during the 15 days of analysis. The Red Californian earthworm hydrolysate presents bioactive compounds identified with antihypertensive activities , and in different isolated and animal models. The study demonstrates the efficacy of the hydrolysate to be used as an alternative in the treatment and prevention of hypertension, and it can be implemented in functional foods or nutraceutical foods. Antihypertensive peptides, particularly those that inhibit angiotensin-converting enzyme (ACE), hold significant importance in medical research, specifically in the context of cardiovascular disease treatment, particularly hypertension. The focus on these peptides and the potential implications of their results in medical research can be summarized through several key points: 1) Mechanisms of Action-Antihypertensive peptides function by inhibiting ACE or renin, crucial enzymes in blood pressure regulation. 2)Alternatives to Synthetic Drugs, 3) Additional Health Benefits, and various other factors.

中文翻译：

---

加州红虫 (Eisenia fetida) 蛋白酶解产物的体外、离体和体内抗高血压评价


高血压是伴随心血管疾病 (CVD) 状态的重要危险因素，这就是为什么我们开始使用兔主动脉环和诱发高血压的大鼠来评估加州红虫水解物的抗高血压活性。人工分离虫体，用水冲洗，用4%碳酸氢钠吹扫4 h，用7%生理盐水处死，最后用饮用水冲洗。通过测量血管紧张素转换酶抑制作用来评估降压能力；在测定中，使用兔主动脉来测量松弛；对于测定，使用诱导高血压的大鼠进行急性（低血压）和慢性测定，在所有测定中使用卡托普利作为对照。对于血管紧张素转换酶（ACE）抑制作用，蠕虫水解物的 EC50 值为 358 ppm；关于主动脉环的分析，发现水解产物的作用机制是内皮依赖性的，最大松弛度为 35%。就测定而言，降血压测试表明，水解产物仅在 2 小时内即可将血压降低高达 32%，而慢性分析表明，150 ppm 的水解产物与对照（卡托普利）没有出现统计学上的显着差异。在 15 天的分析期间。加州红蚯蚓水解物在不同的分离模型和动物模型中呈现出具有抗高血压活性的生物活性化合物。该研究证明了水解产物作为治疗和预防高血压的替代品的功效，并且可以在功能性食品或营养食品中实施。 抗高血压肽，特别是那些抑制血管紧张素转换酶（ACE）的肽，在医学研究中具有重要意义，特别是在心血管疾病（尤其是高血压）治疗方面。对这些肽的关注及其在医学研究中的潜在意义可以概括为几个关键点：1）作用机制——抗高血压肽通过抑制ACE或肾素（血压调节中的关键酶）发挥作用。 2) 合成药物的替代品，3) 额外的健康益处，以及各种其他因素。